Press Releases

Browse the archive

Lachen, Switzerland, January 22nd, 2018: Octapharma is delighted to announce the publication                             of final data from a Good Clinical Practice (GCP) trial in PUPs in the internationally                             renowned medical journal Haemophilia. The study...

Lachen, Switzerland, November 21st, 2017: Octapharma is pleased to announce the completion of a charitable donation of 30.5 million international units of its human cell-line derived recombinant factor VIII product, Nuwiq®, in...

Hoboken, New Jersey, October 31st 2017: Octapharma USA has provided a grant to support the final leg of the inspirational journey of Chris Bombardier, who hopes to become the first person with severe Hemophilia to climb....

Hoboken, New Jersey, August 29th 2017: Octapharma USA sponsored the National Hemophilia Foundation’s 69th Annual Meeting in Chicago and provided a patient symposium sharing the inspirational stories of three young men with...

Lachen, Switzerland, August 23rd 2017: Octapharma is delighted to announce the publication of interim data from the NuProtect study (GENA-05, NCT01712438), the first clinical data on treatment with Nuwiq® in previously...

Lachen, Switzerland, July 11th 2017: Octapharma is pleased to announce the success of yesterday’s symposium at the International Society on Thrombosis and Haemostasis (ISTH) congress held in Berlin, Germany. As platinum sponsors...

Lachen, Switzerland, July 10th 2017: Octapharma is playing a prominent role this week at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Berlin, Germany. As a platinum sponsor of the congress,...

Lachen, Switzerland, July 6th, 2017 – Octapharma today announced that it will be actively involved in a wide range of activities at this year’s International Society on Thrombosis and Haemostasis (ISTH) Congress. The Congress...

Lachen, Switzerland, December 22nd, 2016: Octapharma is proud to announce that the company has made a charitable donation of 4.5 million units of its fourth generation, human cell-line derived recombinant factor VIII product,...